CLINICAL_TRIALS
trial_result
· 2011-10-13
Clinical Trial Update: Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study [Phase 3]
Summary
A phase 3 neoadjuvant study (Neo ALTTO) comparing lapatinib and/or trastuzumab for breast neoplasms has completed with results posted in 2011.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Neoplasms, Breast | Phase 3 | Status: COMPLETED | Results posted: 2011-10-13